Skip subpage navigation
In the event the class of drugs specified herein has previously been reviewed, the government solicits quotes for new Blanket Purchase Agreements (BPAs)/Voluntary Agreement for Retail Refunds (VARRs) to replace any existing BPAs/VARRs. The government will not consider existing BPA/VARR prices in the Uniform Formulary (UF) evaluation. Any existing BPA/VARR for this class of drugs will be terminated upon the conclusion of the UF decision.
| Meeting Date |
Review Type |
Drug Classes/New Drugs Under Review/Information for Manufacturers |
Meeting Window for Manufacturers to give Clinical/Cost Presentation |
|
February 2015
|
Class Review |
Oral Oncological Agents/Prostate I & II |
December 2014
Belsomra - Solicitation Cancelled
|
| Class Review |
Transmucosal Immediate Rlease Fentanyl |
| Class Review |
Pulmonary Aterial Hypertension Agents |
| Designated Newly Approved Drugs |
Zonitivity, Hetlioz, Belsomra, Jardiance, Esomeprasole Strontium, Stendra |
|
May 2015
|
Class Review |
Newer Oral Anticoagulants and Warfarin |
March 2015 |
| Class Review |
Hepatitis Antivirals (Hepatitis C) |
| Designated Newly Approved Drugs |
Belsomra, Plegridy, Diclegis |
| August 2015 |
Class Review |
Diabetes Non-Insulin (GLP-1 Receptor Agonists) |
June 2015
|
| Class Review |
Diabetes Non-Insulin (SGLT-2 Inhibitors) |
| Class Review |
Narcotic Analgesics - Long Acting |
| Class Review |
Oncological Agents - CML Drugs |
| Designated Newly Approved Drugs |
Incruse Ellipta, Cosentyx |
| November 2015 |
Class Review |
Attention Deficit Hyperactivity Disorder - Stimulants |
October 2015
|
| Class Review |
Antirheumatics - Injectable Methorexate |
| Class Review |
Gastrointestinal-2 Agents - Miscellaneous |
| Class Reveiw |
Acne - Isotretinoids |
| Designated Newly Approved Drugs |
Namenda XR, Namzaric |
Subject to Change Disclaimer
The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.
If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: April 25, 2024